4Dmedical stock has an AUD 4.37 target from three analysts

Published on 10/15/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The AGM is scheduled for October 28, 2026. 4Dmedical stock costs EUR 2.52 on October 15, 2026 at 6:37 p.m. CEST after hours.

Analyst target and annual meeting

Three analysts set an AUD 4.37 average target for 4DMedical as of October 15, 2026.
4DMedical's annual general meeting is scheduled for October 28, 2026.
4Dmedical stock costs EUR 2.52 at Lang & Schwarz on October 15, 2026 at 6:37 p.m. CEST.
4DMedical had an AUD 2.5 billion market capitalization on October 15, 2026.

4Dmedical, AU0000095416, Illustration mit AI erstellt.

4Dmedical (ISIN AU0000095416) had an AUD 4.37 average analyst target from three analysts as of October 15, 2026, according to StockAnalysis. At Lang & Schwarz, the stock was trading at EUR 2.52 on October 15, 2026 at 6:37 p.m. CEST after hours.

Target and meeting set the frame

The AUD 4.37 target sits AUD 0.29 above the ASX price of AUD 4.08 on October 15, 2026, a 7.11 percent difference. The target and the Hold consensus cover three analysts, giving the valuation discussion a defined reference point rather than a broad market label, according to StockAnalysis.

4DMedical's 2026 annual general meeting is scheduled for October 28, 2026, at 10 a.m. Australian Eastern Daylight Time, according to the company's investor services page. The date gives investors the next formal point for company updates.

Revenue remains small against valuation

StockAnalysis lists last-twelve-month revenue of AUD 7.06 million and a net loss of AUD 204.44 million for 4DMedical. The same page reports a market capitalization of AUD 2.5 billion and 601.57 million shares outstanding as of October 15, 2026, according to StockAnalysis.

On the ASX, 4DMedical closed at AUD 4.08 on October 15, 2026, up 7.37 percent from AUD 3.80. Its AUD 1.40 to AUD 7.55 52-week range places the closing price 45.96 percent below the high. The company develops lung-imaging technology and software for respiratory diagnostics, with its ASX listing and 4DX code identified on its investor page.

Comparison with peers

4Dmedical (ASX, AUD): plus 7.37 percent, market capitalization AUD 2.5 billion

Pro Medicus (ASX, AUD): minus 0.20 percent, P/E 64.40, market capitalization AUD 17.1 billion

ResMed (ASX, AUD): plus 0.03 percent, P/E 23.16, market capitalization AUD 47.3 billion

Price and investor perspective

The euro quote provides the German trading perspective, while the ASX figures show the company's home-market valuation and daily positioning. The next scheduled corporate date is October 28, 2026.

4Dmedical was trading at EUR 2.52 at Lang & Schwarz on October 15, 2026 at 6:37 p.m. CEST after hours. The further course of trading is shown by the continuously updated real-time quote of 4Dmedical stock.